Ginkgo biloba drugs will continue to ferment after special treatment, and those who do not have extraction capacity will stop production next year

Provenance: great wisdom astak news agency may 25, 2015, great wisdom astak news agency, Guilin Xingda Pharmaceutical Co., Ltd changed the production process of ginkgo leaf extraction without authorization, and the incident reported by the State Food and drug administration to investigate and deal with was upgraded again Wu Zhen, deputy director of CFDA, said on Friday that CFDA attaches great importance to the special treatment of Ginkgo biloba drugs, and at the same time, we should draw inferences from one example and do a good job in the management of Chinese herbal extracts From next year, the production of Chinese herbal medicines can no longer be entrusted for extraction Any Chinese patent medicine production enterprise that does not have the ability to extract Chinese herbal medicines will stop the production of corresponding varieties Wu Zhen said that the General Administration had issued a special notice on the incident, held a press conference, and issued a notice on the deployment of Ginkgo biloba drugs special treatment by Mingchuan telegram The purpose of the video conference was to clarify the significance of special treatment He stressed that the special treatment of Ginkgo biloba drugs requires strict investigation and punishment of the discovered illegal acts, a thorough investigation of the existing case clues and a comprehensive clean-up of the Ginkgo biloba drug market "On May 20, the General Administration informed the Supreme People's Procuratorate, the Supreme People's court, the Ministry of public security and the health and Family Planning Commission about the cases It hoped that the two cases could be completed as iron cases, and demonstrated the authority of the regulatory authorities At the same time, it made the violators deeply realize that they would pay a heavy price for defying the law and taking risks." Wu Zhen asked that we should draw inferences from one example and do a good job in the management of Chinese herbal extracts After the circular on strengthening the supervision and management of Chinese herbal extracts in production was issued by the General Administration, it was seriously implemented and achieved some results, but the long-term problems are not solved overnight According to the requirements of the above documents, from January 1, 2016, the production of traditional Chinese medicine shall not be entrusted to extract any more Any Chinese patent medicine production enterprise that does not have the ability to extract traditional Chinese medicine shall stop the production of corresponding varieties, and the purchased extract must be in accordance with the regulations CFDA previously reported that Guilin Xingda Pharmaceutical Co., Ltd and Wanbang (Hunan) Natural Medicine Co., Ltd illegally produced extracts and sold products to other enterprises, including 24 enterprises including Yunnan Baiyao (000538 SZ), Qianyuan Pharmaceutical (300254 SZ) and Fangsheng Pharmaceutical (603998 SH) were involved in the incident Subsequently, Qianyuan pharmaceutical and Fangsheng pharmaceutical announced that they had started the recall of related drugs However, Yunnan Baiyao claimed that the company and its affiliated production units did not produce any preparation products containing ginkgo biloba extract before, and had never used the Ginkgo biloba extract mentioned in the circular.